Autopsy report · NCT02340156
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Cause of deathNo reason given
Life of this trial
- Ran for about 3 years 11 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- SynerGene Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- RECURRENT GLIOBLASTOMA
- Interventions
- SGT-53; Temozolomide
- Participants
- 1
- Sites
- 2
- Countries
- Taiwan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.